MDLN
Research Snapshot
Static fundamentals, valuation context, and investor signals for Medline Inc. (MDLN).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
10775.8%
ROIC, 4.6% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 4.3x current ratio
Superinvestors
4
Top: Stephen Mandel (4.2%)
Strengths to research
- Return on equity is strong at 10775.8%.
- Debt/equity looks manageable at 0.0x.
- 4 tracked superinvestors report a position.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 4 periods
Quarterly data: 4 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for MDLN.
Grade D
40
/ 100
Financial Charts
No financial data available for MDLN (annual).
4 superinvestors own MDLN
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Stephen Mandel Lone Pine Capital | 11,789,156 | $525M | 4.18% | 0.0% |
| Viking Global Investors Viking Global Investors | 11,433,992 | $509M | 1.42% | 0.0% |
| John Armitage Egerton Capital | 4,365,802 | $194M | 2.16% | 0.0% |
| Lee Ainslie Maverick Capital | 796,077 | $35M | 0.41% | 0.0% |